Enhancements in breast imaging mark the latest ultrasound upgrade from Philips Healthcare. Tissue aberration correction technology and algorithms built into the Vision 2009 upgrade for its iU22 radiological flagship are part of an integrated effort to better define tissue in fatty breasts, according to the company. An enabling technology is the Philips PureWave transducer and its coded beamformer, which have been present on earlier technologies.
Enhancements in breast imaging mark the latest ultrasound upgrade from Philips Healthcare. Tissue aberration correction technology and algorithms built into the Vision 2009 upgrade for its iU22 radiological flagship are part of an integrated effort to better define tissue in fatty breasts, according to the company. An enabling technology is the Philips PureWave transducer and its coded beamformer, which have been present on earlier technologies.
Tissue aberration correction, which was devised initially to look at obese patients, compensates for speed of sound variations of dense tissue, improving detail resolution and conspicuity of lesion details. Another major addition of Vision 2009 is the VL13-5 high-frequency volume linear transducer, which is clinically optimized for breast, thyroid, carotid, and general applications.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
FDA Clears Updated AI Platform for Digital Breast Tomosynthesis
November 12th 2024Employing advanced deep learning convolutional neural networks, ProFound Detection Version 4.0 reportedly offers a 50 percent improvement in detecting cancer in dense breasts in comparison to the previous version of the software.